Kodiak Sciences Inc.
NASDAQ:KOD
3.84 (USD) • At close November 1, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Kodiak Sciences Inc. |
Symbool | KOD |
Munteenheid | USD |
Prijs | 3.84 |
Beurswaarde | 202,040,448 |
Dividendpercentage | 0% |
52-weken bereik | 1.59 - 7.77 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Victor Perlroth M.D. |
Website | https://kodiak.com |
An error occurred while fetching data.
Over Kodiak Sciences Inc.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)